Search clinical trials for: CV09050101 mRNA vaccine (CVGBM) 50 μg

Total 8 results

CureVac

Active, not recruiting

Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma

Glioblastoma

Belgium, Germany, Netherlands
CNBG-Virogin Biotech (Shanghai) Ltd.
Shulan (Hangzhou) Hospital

Recruiting

A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

SARS-CoV-2 Infection

China
CureVac
German Federal Ministry of Education and Research

Completed

A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

Severe Acute Respiratory Syndrome | Covid19 | SARS-CoV-2 | Coronavirus

Panama, Peru
Sanofi

Terminated

Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity

Clostridium Difficile Infection | Clostridium Difficile Diarrhea
Bayer
CureVac

Withdrawn

COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older (CV-NCOV-011)

Coronavirus Disease 2019 (COVID-19) | SARS-CoV-2 Infection
U.S. Army Medical Research and Development Command

Completed

Booster Dose (50 µg) of Recombinant Ricin Toxin Vaccine (RVEc™) in Previously Vaccinated Healthy Adults (RVEc)

Ricin Poisoning

United States
U.S. Army Medical Research and Development Command

Completed

Phase 1 Safety and Immunogenicity of Meningococcal Vaccine (HOPS)

Meningococcal Infection, Group B

United States
University Hospital, Basel, Switzerland
Swiss National Science Foundation; ModernaTX, Inc.

Completed

Immunocompromised Swiss Cohorts Based Trial Platform (COVERALL)

Immunocompromised Patients

Switzerland

3

Subscribe